Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

Area of Science:

• Molecular Biology
• Cancer Research
• DNA Repair Mechanisms

Background:

• PARP inhibitors (PARPi) induce DNA single-strand breaks (SSBs), leading to replication stress (RS) and lesions.
• Homologous recombination repair (HRR) is crucial for resolving these lesions; defects, like BRCA2 mutations, confer PARPi sensitivity.
• CHK1 kinase plays a dual role in responding to RS by signaling cell cycle checkpoints and promoting HRR.

Purpose of the Study:

• To investigate the relative contributions of CHK1's cell cycle checkpoint and HRR functions to survival following PARPi exposure.
• To determine the impact of combined PARPi (rucaparib) and CHK1 inhibitor (PF-477736) treatment on cells with varying BRCA2 status.

Main Methods:

• Utilized isogenic cell lines with mutated (V-C8) and corrected (V-C8.B2) BRCA2.
• Administered rucaparib and PF-477736 alone and in combination.
• Assessed cytotoxicity, replication stress (γH2AX foci), and HRR activity (RAD51 foci).

Main Results:

• BRCA2-mutated cells showed extreme sensitivity to rucaparib but not PF-477736.
• PF-477736 significantly enhanced rucaparib cytotoxicity in BRCA2-corrected cells but not in BRCA2-mutated cells.
• PF-477736 increased rucaparib-induced replication stress and abolished RAD51 foci, indicating HRR suppression.

Conclusions:

• CHK1 inhibition sensitizes cells to PARPi primarily by suppressing HRR, rather than through cell cycle checkpoint inhibition.
• The combination therapy's efficacy is dependent on HRR proficiency, highlighting HRR status as a key determinant of response.